Habek, M. (2021). Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis. Neurological Sciences, 42. (10), 4003-4005. doi: 10.1007/s10072-021-05495-6
Habek, Mario. "Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis." Neurological Sciences, vol. 42, no. 10, 2021, pp. 4003-4005. https://doi.org/10.1007/s10072-021-05495-6
Habek, Mario. "Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis." Neurological Sciences 42, no. 10 (2021): 4003-4005. https://doi.org/10.1007/s10072-021-05495-6
Habek, M. (2021) 'Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis', Neurological Sciences, 42(10), pp. 4003-4005. doi: 10.1007/s10072-021-05495-6
Habek M. Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis. Neurological Sciences [Internet]. 2021 July 31 [cited 2024 August 21];42(10):4003-4005. doi: 10.1007/s10072-021-05495-6
M. Habek, "Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis", Neurological Sciences, vol. 42, no. 10, pp. 4003-4005, July 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:479687. [Accessed: 21 August 2024]